|
ADO expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.13860032513458E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.68399977190847E-10 |
| Normal-vs-Stage2 |
1.66617999999286E-05 |
| Normal-vs-Stage3 |
2.57459609187549E-11 |
| Normal-vs-Stage4 |
1.13742348872847E-12 |
| Stage1-vs-Stage2 |
1.136820E-01 |
| Stage1-vs-Stage3 |
1.511000E-01 |
| Stage1-vs-Stage4 |
1.394000E-02 |
| Stage2-vs-Stage3 |
2.809800E-02 |
| Stage2-vs-Stage4 |
2.482700E-03 |
| Stage3-vs-Stage4 |
1.726360E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.95869995170506E-11 |
| Normal-vs-AfricanAmerican |
2.65129999998948E-06 |
| Normal-vs-Asian |
1.68790004195785E-09 |
| Caucasian-vs-AfricanAmerican |
2.928000E-01 |
| Caucasian-vs-Asian |
5.277400E-01 |
| AfricanAmerican-vs-Asian |
5.820800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.87809800833838E-11 |
| Normal-vs-Female |
2.41650033316887E-10 |
| Male-vs-Female |
2.903400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.58239976677521E-10 |
| Normal-vs-Age(41-60Yrs) |
8.79980532886293E-11 |
| Normal-vs-Age(61-80Yrs) |
1.79949999346007E-09 |
| Normal-vs-Age(81-100Yrs) |
5.619900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.221400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.155000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.986800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.016200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.622800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.406800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.344380E-02 |
| Classical-VS-Follicular |
5.119700E-02 |
| Classical-VS-Other |
3.948600E-01 |
| Classical-VS-Normal |
2.03119965291876E-10 |
| Tall-VS-Follicular |
7.982700E-04 |
| Tall-VS-Other |
8.984200E-01 |
| Tall-VS-Normal |
4.79705164480038E-12 |
| Follicular-VS-Other |
2.227200E-01 |
| Follicular-VS-Normal |
2.43290000034868E-07 |
| Other-VS-Normal |
1.255730E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.74439995781484E-09 |
| Normal-vs-N1 |
1.85407245112401E-13 |
| N0-vs-N1 |
2.817400E-04 |
|
|
